Elpro International Ltd acquired equity shares in Cohance Lifesciences Ltd for investment purposes via cash consideration.
Cohance reported consolidated FY25 revenue of ₹1,197.58 crore and total income of ₹1,256.14 crore.
The acquisition is not a related party transaction and required no governmental or regulatory approvals.
Elpro's total holding post-acquisition stands at 248,813 equity shares in the pharmaceutical company.